Shares of micro-cap biotech company Corbus Pharmaceuticals (NASDAQ:CRBP) skyrocketed over 300% on Friday following the announcement of early, yet promising, data from a small group of cancer patients who were treated with its antibody-drug conjugate CRB-701 in a Phase 1 trial.
Based on the data cut in December for patients with cancers expressing the tumor-associated antigen nectin-4, Corbus (CRBP) reported that CRB-701 resulted in an objective response rate (ORR) of 43%, including three partial responses.
The company unveiled the data from the first eighteen participants who received the initial six dose levels, which formed part of its Phase 1 dose escalation study for CRB-701 conducted by its partner CSPC Pharmaceutical Group (OTCPK:CSPCY) (OTCPK:CHJTF) in China.
With dosing up to 3.6 mg/kg completed, there were no dose discontinuations or reductions, and most adverse events were grade one or two and reversible, according to the company.
Dosing for the 4.5 mg/kg group is currently ongoing, and the company plans to commence a U.S. clinical trial for CRB-701 (SYS6002) in Q1 2024.
